Truist upgrades Biogen to Buy, raises target to $235
Truist Securities analyst Srikripa Devarakonda upgraded Biogen Inc from Hold to Buy, increasing the price target from $190 to $235. Biogen shares closed at $199.15 on Friday.

*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Srikripa Devarakonda has upgraded Biogen Inc from Hold to Buy, raising the price target to $235 from $190. The rating change reflects a more positive outlook on the stock's performance potential. Biogen shares closed at $199.15 on Friday.
Rating and Target Changes
The upgrade moves Biogen out of a neutral stance, signaling confidence in future gains. The new price target of $235 represents a significant increase from the previous $190 level.
| Metric | Previous | New |
|---|---|---|
| Rating | Hold | Buy |
| Price Target | $190 | $235 |
What specific factors or upcoming catalysts drove Truist Securities to shift its outlook to positive?
How might this upgrade influence other analysts' ratings and overall market sentiment for Biogen?
What are the expected timelines for Biogen to reach the new $235 price target?

































